Full-Time

Principal Scientist

Molecular Biology

Confirmed live in the last 24 hours

Generation Bio

Generation Bio

51-200 employees

Develops durable genetic treatments for diseases

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD in Molecular Biology, Cell Biology, Synthetic biology, Bioengineering, Biochemistry or related discipline.
  • Minimum of 6 years of relevant experience, majority in an industry setting.
  • Experience in scientific fields of nuclear pore complex structure/ function, cellular trafficking of diverse cargos, mechanism of mRNA export, viral packaging and nuclear translocation, or related field.
  • Capacity for innovative thinking and critical problem solving.
  • Excellent communication and interpersonal skills with capacity and proven track record of working cross functionally.
Responsibilities
  • Lead design approaches for optimizing nuclear translocation of nucleic acid cargoes.
  • Generate appropriately scoped research plans to meet scientific and resourcing demands.
  • Lead execution of research individually and as part of function and cross functional teams.
  • Present scientific ideas and results effectively to different teams and groups within the organization.
  • Accountable for on-time execution of experimental projects to advance our iqDNA platform.

Generation Bio focuses on developing genetic treatments for both rare and common diseases. Their main product is based on a non-viral genetic medicine platform that includes iqDNA, which is designed to be immune-quiet, and ctLNP, a delivery system that targets specific cells. This platform allows for the creation of treatments that can last for several years from a single dose and can be adjusted for patient needs through redosing. They use a unique manufacturing process called rapid enzymatic synthesis (RES) that enables them to produce large quantities of their genetic medicine efficiently. Unlike many competitors, Generation Bio aims to make these treatments widely accessible by scaling production to meet high demand. The company's goal is to address significant medical needs by providing durable and effective genetic therapies.

Company Stage

IPO

Total Funding

$252.9M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-25%

2 year growth

-15%
Simplify Jobs

Simplify's Take

What believers are saying

  • The development of iqDNA and ctLNP platforms positions Generation Bio at the forefront of genetic medicine innovation, potentially leading to breakthrough treatments for rare and prevalent diseases.
  • Strategic reorganization and cost-saving measures extend the company's cash runway into the second half of 2027, providing financial stability and continued investment in R&D.
  • High-profile presentations at conferences and collaborations with industry leaders like Moderna enhance the company's visibility and credibility in the biotech sector.

What critics are saying

  • The 40% workforce reduction as part of the strategic reorganization could impact employee morale and productivity.
  • Dependence on successful integration and advancement of iqDNA and ctLNP platforms carries inherent risks if the technologies do not perform as expected in clinical settings.

What makes Generation Bio unique

  • Generation Bio's focus on non-viral genetic medicines using proprietary immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms sets it apart from traditional gene therapy companies.
  • Their scalable capsid-free manufacturing process, utilizing rapid enzymatic synthesis (RES), offers a unique advantage in producing genetic medicines efficiently.
  • The strategic collaboration with Moderna highlights Generation Bio's innovative approach and industry recognition.

Help us improve and share your feedback! Did you find this helpful?